Latest Insider Transactions at Fate Therapeutics Inc (FATE)
This section provides a real-time view of insider transactions for Fate Therapeutics Inc (FATE). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of FATE THERAPEUTICS INC to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of FATE THERAPEUTICS INC's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 02
2021
|
Timothy Coughlin |
BUY
Grant, award, or other acquisition
|
Direct |
2,681
+4.34%
|
-
|
|
Jun 02
2021
|
Robert Hershberg Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,681
+50.0%
|
-
|
|
Jun 02
2021
|
Redmile Group, LLC Director |
BUY
Grant, award, or other acquisition
|
Indirect |
2,681
+0.02%
|
-
|
|
May 20
2021
|
J Scott Wolchko President and CEO |
SELL
Open market or private sale
|
Direct |
20,000
-4.83%
|
$1,540,000
$77.16 P/Share
|
|
May 20
2021
|
J Scott Wolchko President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+4.61%
|
$80,000
$4.84 P/Share
|
|
Apr 23
2021
|
J Scott Wolchko President and CEO |
SELL
Open market or private sale
|
Direct |
30,000
-7.08%
|
$2,550,000
$85.24 P/Share
|
|
Apr 23
2021
|
J Scott Wolchko President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+2.35%
|
$120,000
$4.73 P/Share
|
|
Apr 22
2021
|
J Scott Wolchko President and CEO |
SELL
Open market or private sale
|
Direct |
30,000
-7.08%
|
$2,550,000
$85.54 P/Share
|
|
Apr 22
2021
|
J Scott Wolchko President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+6.61%
|
$60,000
$2.73 P/Share
|
|
Apr 16
2021
|
Yu Waye Chu Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
3,275
-1.63%
|
$271,825
$83.04 P/Share
|
|
Apr 01
2021
|
Cindy Tahl |
SELL
Open market or private sale
|
Direct |
30,000
-3.0%
|
$2,520,000
$84.09 P/Share
|
|
Apr 01
2021
|
Cindy Tahl |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+9.23%
|
$150,000
$5.39 P/Share
|
|
Mar 15
2021
|
Bahram Valamehr President and CEO |
SELL
Open market or private sale
|
Direct |
25,000
-4.5%
|
$2,300,000
$92.76 P/Share
|
|
Mar 15
2021
|
Bahram Valamehr President and CEO |
SELL
Exercise of conversion of derivative security
|
Direct |
25,000
-17.15%
|
$50,000
$2.9 P/Share
|
|
Mar 08
2021
|
Daniel D Shoemaker Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
25,000
-3.61%
|
$2,050,000
$82.55 P/Share
|
|
Feb 18
2021
|
J Scott Wolchko President and CEO |
SELL
Open market or private sale
|
Direct |
20,000
-0.98%
|
$2,020,000
$101.28 P/Share
|
|
Feb 18
2021
|
J Scott Wolchko President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+4.61%
|
$120,000
$6.62 P/Share
|
|
Jan 22
2021
|
J Scott Wolchko President and CEO |
SELL
Open market or private sale
|
Direct |
30,000
-1.82%
|
$2,940,000
$98.76 P/Share
|
|
Jan 22
2021
|
J Scott Wolchko President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+3.46%
|
$120,000
$4.68 P/Share
|
|
Jan 21
2021
|
J Scott Wolchko President and CEO |
SELL
Open market or private sale
|
Direct |
30,000
-0.91%
|
$3,090,000
$103.59 P/Share
|
|
Jan 21
2021
|
J Scott Wolchko President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+6.61%
|
$60,000
$2.73 P/Share
|
|
Jan 20
2021
|
Edward J Dulac Iii Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
18,013
+23.69%
|
-
|
|
Jan 20
2021
|
Daniel D Shoemaker Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
14,411
+12.82%
|
-
|
|
Jan 20
2021
|
Cindy Tahl |
BUY
Grant, award, or other acquisition
|
Direct |
18,013
+14.29%
|
-
|
|
Jan 20
2021
|
Bahram Valamehr President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
18,013
+15.84%
|
-
|
|
Jan 20
2021
|
J Scott Wolchko President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
43,231
+9.89%
|
-
|
|
Jan 19
2021
|
Cindy Tahl |
SELL
Open market or private sale
|
Direct |
35,000
-7.71%
|
$4,025,000
$115.56 P/Share
|
|
Jan 19
2021
|
Cindy Tahl |
BUY
Exercise of conversion of derivative security
|
Direct |
35,000
+21.87%
|
$70,000
$2.9 P/Share
|
|
Jan 11
2021
|
Daniel D Shoemaker Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
3,253
-1.26%
|
$357,830
$110.68 P/Share
|
|
Jan 11
2021
|
Cindy Tahl |
SELL
Open market or private sale
|
Direct |
3,254
-1.18%
|
$357,940
$110.68 P/Share
|
|
Jan 11
2021
|
Bahram Valamehr President and CEO |
SELL
Open market or private sale
|
Direct |
3,254
-1.36%
|
$357,940
$110.68 P/Share
|
|
Jan 11
2021
|
J Scott Wolchko President and CEO |
SELL
Open market or private sale
|
Direct |
8,587
-0.8%
|
$944,570
$110.68 P/Share
|
|
Jan 08
2021
|
Daniel D Shoemaker Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
6,229
-1.71%
|
$722,564
$116.33 P/Share
|
|
Jan 08
2021
|
Cindy Tahl |
SELL
Open market or private sale
|
Direct |
6,229
-1.6%
|
$722,564
$116.33 P/Share
|
|
Jan 08
2021
|
Bahram Valamehr President and CEO |
SELL
Open market or private sale
|
Direct |
6,230
-1.83%
|
$722,680
$116.33 P/Share
|
|
Jan 08
2021
|
J Scott Wolchko President and CEO |
SELL
Open market or private sale
|
Direct |
60,820
-3.8%
|
$7,055,120
$116.33 P/Share
|
|
Jan 08
2021
|
Redmile Group, LLC Director |
BUY
Open market or private purchase
|
Indirect |
327,485
+2.47%
|
$27,836,225
$85.5 P/Share
|
|
Dec 17
2020
|
J Scott Wolchko President and CEO |
SELL
Open market or private sale
|
Direct |
20,000
-1.15%
|
$1,840,000
$92.28 P/Share
|
|
Dec 17
2020
|
J Scott Wolchko President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+4.35%
|
$120,000
$6.62 P/Share
|
|
Dec 14
2020
|
Bahram Valamehr President and CEO |
SELL
Open market or private sale
|
Direct |
25,000
-3.05%
|
$2,475,000
$99.32 P/Share
|
|
Dec 14
2020
|
Bahram Valamehr President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+18.22%
|
$50,000
$2.9 P/Share
|
|
Nov 16
2020
|
Daniel D Shoemaker Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
25,000
-7.52%
|
$1,275,000
$51.46 P/Share
|
|
Nov 13
2020
|
J Scott Wolchko President and CEO |
SELL
Open market or private sale
|
Direct |
30,000
-2.33%
|
$1,530,000
$51.03 P/Share
|
|
Nov 13
2020
|
J Scott Wolchko President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+2.27%
|
$150,000
$5.74 P/Share
|
|
Nov 12
2020
|
J Scott Wolchko President and CEO |
SELL
Open market or private sale
|
Direct |
30,000
-1.7%
|
$1,590,000
$53.18 P/Share
|
|
Nov 12
2020
|
J Scott Wolchko President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+6.25%
|
$60,000
$2.73 P/Share
|
|
Nov 05
2020
|
Cindy Tahl |
SELL
Open market or private sale
|
Direct |
19,282
-8.29%
|
$964,100
$50.85 P/Share
|
|
Nov 05
2020
|
Cindy Tahl |
BUY
Exercise of conversion of derivative security
|
Direct |
19,282
+7.81%
|
$38,564
$2.82 P/Share
|
|
Nov 04
2020
|
Cindy Tahl |
SELL
Open market or private sale
|
Direct |
51,519
-34.11%
|
$2,575,950
$50.41 P/Share
|
|
Nov 04
2020
|
Cindy Tahl |
BUY
Exercise of conversion of derivative security
|
Direct |
51,519
+25.43%
|
$103,038
$2.73 P/Share
|